Moderna (MRNA) Interest & Investment Income (2018 - 2026)

Moderna has reported Interest & Investment Income for 9 years, with the latest figure at $67.0 million in Q2 2026.

• Interest & Investment Income for Q2 2026 came in at $67.0 million, down 17.28% year-over-year; the trailing twelve-month figure through Jun 2026 was $282.0 million (down 22.74% YoY), and the FY2025 annual result was $314.0 million, down 26.12% from the prior year.
• Interest & Investment Income eased to $67.0 million in Q2 2026, from $72.0 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $120.0 million in Q1 2024 and troughed at $15.0 million in Q1 2022.
• A 5-year average of $83.3 million and a median of $88.5 million in 2022 frame the typical range for Interest & Investment Income.
• The widest annual swing landed in 2022, when Interest & Investment Income jumped 1350.0%; it then slipped 29.13% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $87.0 million in 2022, then climbed by 18.39% to $103.0 million in 2023, then declined by 11.65% to $91.0 million in 2024, then retreated by 23.08% to $70.0 million in 2025, then slipped by 4.29% to $67.0 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $67.0 million in Q2 2026, $72.0 million in Q1 2026, and $70.0 million in Q4 2025.